ES2093935T3 - Esquizofrenia. - Google Patents

Esquizofrenia.

Info

Publication number
ES2093935T3
ES2093935T3 ES93309286T ES93309286T ES2093935T3 ES 2093935 T3 ES2093935 T3 ES 2093935T3 ES 93309286 T ES93309286 T ES 93309286T ES 93309286 T ES93309286 T ES 93309286T ES 2093935 T3 ES2093935 T3 ES 2093935T3
Authority
ES
Spain
Prior art keywords
schizophrenia
acid
epas
treated
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93309286T
Other languages
English (en)
Inventor
David Frederick Horrobin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scotia Holdings PLC
Original Assignee
Scotia Holdings PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scotia Holdings PLC filed Critical Scotia Holdings PLC
Application granted granted Critical
Publication of ES2093935T3 publication Critical patent/ES2093935T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

LOS SINTOMAS NEGATIVOS DE ESQUIZOFRENIA Y/O BAJOS NIVELES DE MEMBRANA CELULAR DE EFAS PUEDEN SER TRATADOS CON UNA COMBINACION DE ACIDO ARAQUIDONICO Y ACIDO DOCOSAHEXANOICO.
ES93309286T 1992-11-26 1993-11-22 Esquizofrenia. Expired - Lifetime ES2093935T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929224809A GB9224809D0 (en) 1992-11-26 1992-11-26 Schizophrenia

Publications (1)

Publication Number Publication Date
ES2093935T3 true ES2093935T3 (es) 1997-01-01

Family

ID=10725730

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93309286T Expired - Lifetime ES2093935T3 (es) 1992-11-26 1993-11-22 Esquizofrenia.

Country Status (19)

Country Link
US (1) US5516800A (es)
EP (2) EP0733360A3 (es)
JP (1) JPH06199663A (es)
CN (1) CN1104494A (es)
AT (1) ATE144706T1 (es)
AU (2) AU666782B2 (es)
CA (1) CA2109777A1 (es)
DE (1) DE69305723T2 (es)
DK (1) DK0599576T3 (es)
ES (1) ES2093935T3 (es)
GB (1) GB9224809D0 (es)
GR (1) GR3021692T3 (es)
HK (1) HK114297A (es)
MY (1) MY109905A (es)
NO (1) NO934266L (es)
NZ (1) NZ250265A (es)
RU (1) RU2123844C1 (es)
SG (1) SG47838A1 (es)
ZA (1) ZA938835B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994392A (en) * 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US20050027004A1 (en) * 1993-06-09 2005-02-03 Martek Biosciences Corporation Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions
CA2164291C (en) * 1993-06-09 2007-10-30 David John Kyle Methods and pharmaceutical compositions useful for treating neurological disorders
GB9510636D0 (en) * 1995-05-25 1995-07-19 Scotia Holdings Plc Fatty acid treatment
EP1886679A3 (en) * 1995-06-07 2008-05-28 Martek Biosciences Corporation Methods for controlling highly unsaturated fatty acid content in various tissues
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
ES2151277T3 (es) * 1996-05-22 2000-12-16 Protarga Inc Composiciones que comprenden conjugados de acido cis-docosahexaenoico y taxotere.
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
CN1109543C (zh) 1996-10-11 2003-05-28 斯卡里斯塔有限公司 包括二十碳五烯酸和/或十八碳四烯酸的药物制剂
US5955459A (en) * 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
US5977174A (en) * 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
US6225444B1 (en) 1998-02-10 2001-05-01 Protarga, Inc. Neuroprotective peptides and uses thereof
ATE361066T1 (de) * 1998-10-15 2007-05-15 Dsm Ip Assets Bv Polyungesättigen fettsäuren nährungsergänzung
GB9826899D0 (en) * 1998-12-08 1999-01-27 Knoll Ag Methods to treat depression and other psychiatric disorders and assays for compounds
HUP0104760A2 (hu) * 1998-12-15 2002-04-29 American Home Products Corporation Eljárás és készítmény a bél épségének megtartására és helyreállítására
GB9901808D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Drugs for treatment of psychiatric and brain disorders
US7235583B1 (en) 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
GB9923738D0 (en) * 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
GB0016045D0 (en) * 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
ES2387562T3 (es) * 2001-03-23 2012-09-26 Luitpold Pharmaceuticals, Inc. Conjugados alcohol graso-medicamento
EP1427407A4 (en) 2001-03-23 2005-05-11 Luitpold Pharm Inc FAT AMIN DRUG CONJUGATES
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
GB0221480D0 (en) * 2002-09-16 2002-10-23 Laxdale Ltd Treatment of anorexia nervosa (AN) and bulimia
EP1713463A4 (en) * 2004-01-19 2009-03-18 Martek Biosciences Corp REELIN DYSFUNCTION OR DICTION AND ASSOCIATED TECHNIQUES
ITMI20040069A1 (it) * 2004-01-21 2004-04-21 Tiberio Bruzzese Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP5967855B2 (ja) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
ITMI20051560A1 (it) * 2005-08-10 2007-02-11 Tiberio Bruzzese Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6
EP1772146A1 (en) * 2005-10-03 2007-04-11 Neuropharma, S.A. Polyunsaturated fatty acids as bace inhibitors
US8637321B2 (en) * 2005-10-24 2014-01-28 Duke University Lipidomics approaches for central nervous system disorders
US8137977B2 (en) * 2006-04-24 2012-03-20 Children's Hospital & Research Center At Oakland Lipidomic approaches to determining drug response phenotypes in cardiovascular disease
EP2098229A4 (en) 2006-12-28 2010-03-10 Suntory Holdings Ltd NERVE REGENERATION MEDIUM
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
CA2704371A1 (en) * 2007-11-01 2009-05-07 Wake Forest University School Of Medicine Compositions and methods for prevention and treatment of mammalian diseases
GB2460056A (en) * 2008-05-14 2009-11-18 Arab Science & Technology Foun Compositions comprising omega-6 fatty acids for use in treating schistosomiasis

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882352A (en) * 1986-07-28 1989-11-21 Nelson Research & Development Co. Method for treating schizophrenia
GB8302708D0 (en) * 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
US4588721A (en) * 1983-09-12 1986-05-13 The Upjohn Company Treatment of negative symptoms of schizophrenia
US4526902A (en) * 1983-10-24 1985-07-02 Century Laboratories, Inc. Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions
GB8601915D0 (en) * 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
GB8603621D0 (en) * 1986-02-14 1986-03-19 Habib N Modifying lipid structure of cell membranes
US5198468A (en) * 1987-06-24 1993-03-30 Efamol Holdings Plc Essential fatty acid composition
GB8714772D0 (en) * 1987-06-24 1987-07-29 Efamol Ltd Essential fatty acid compositions
GB8715914D0 (en) * 1987-07-07 1987-08-12 Efamol Ltd Treatment of cerabral disorders
FR2619712B1 (fr) * 1987-08-25 1990-08-31 Rhone Poulenc Sante Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la schizophrenie
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
HU208484B (en) * 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
DE3920679A1 (de) * 1989-06-23 1991-01-10 Milupa Ag Fettmischung zur herstellung von nahrungen, insbesondere saeuglingsnahrungen
DE4017979A1 (de) * 1990-06-05 1991-12-12 Meyer Lucas Gmbh & Co Lipid- bzw. phospholipid-zusammensetzungen sowie diese enthaltendes mittel zur behandlung von erkrankungen sowie auf die zellmembrane zurueckzufuehrende stoerungen
US5070101A (en) * 1991-02-14 1991-12-03 Mount Sinai School Of Medicine Of The City University Of New York Method and pharmaceutical composition for the treatment of schizophrenia

Also Published As

Publication number Publication date
AU5183093A (en) 1994-06-09
MY109905A (en) 1997-09-30
EP0599576B1 (en) 1996-10-30
GB9224809D0 (en) 1993-01-13
EP0733360A2 (en) 1996-09-25
DK0599576T3 (da) 1996-11-25
HK114297A (en) 1997-08-29
SG47838A1 (en) 1998-04-17
NO934266D0 (no) 1993-11-25
AU666782B2 (en) 1996-02-22
DE69305723D1 (de) 1996-12-05
EP0733360A3 (en) 1996-10-02
NZ250265A (en) 1997-06-24
RU2123844C1 (ru) 1998-12-27
AU5232996A (en) 1996-07-18
CN1104494A (zh) 1995-07-05
ZA938835B (en) 1994-08-02
NO934266L (no) 1994-05-27
ATE144706T1 (de) 1996-11-15
DE69305723T2 (de) 1997-04-03
EP0599576A1 (en) 1994-06-01
GR3021692T3 (en) 1997-02-28
JPH06199663A (ja) 1994-07-19
US5516800A (en) 1996-05-14
CA2109777A1 (en) 1994-05-27

Similar Documents

Publication Publication Date Title
ES2093935T3 (es) Esquizofrenia.
FI944424A7 (fi) Elektrolyysikenno sterilointiliuosten valmistamiseksi joilla on suurem pi otsonipitoisuus
IT1267391B1 (it) Procedimento per l'assemblaggio di una batteria bipolare piombo-acido e batteria bipolare ottenuta con tale procedimento.
GB2180710B (en) Cmos output stage with large voltage swing and with stabilization of the quiescent current
DE69417581D1 (de) Herstellung von lithiumhexafluorphosphatlösungen
DE59607156D1 (de) Fällungskieselsäure
NO931534L (no) Sulfonylbenzylsubstituerte benzo- og pyridopyridoner
DK82786D0 (da) Kombination af flupirtin og anticholinergisk virkende spasmolytica
BR8207771A (pt) Conjunto de membrana de fibra oca microporosa e seu processo de fabricacao
FI832592A0 (fi) Foerfarande foer att utfoera elektromikrobiella reduktioner
DK0460164T3 (da) Stabilisering af hydrogenperoxidopløsninger
DE3770644D1 (de) Monosulfactame.
FI874126L (fi) Anaerobt foerfarande.
DE3882220D1 (de) Herstellung von chlordioxyd in einer elektrolytischen zelle.
BR8101318A (pt) Pilha eletrolitica de membrana monopolar e circuito de pilhas
TR22513A (tr) Stabilize sulu hidrojen peroksit eriyikleri
ES555869A0 (es) Metodo de almacenamiento de residuos nucleares en vidrio durante su fabricacion.
ES2102959B1 (es) Procedimiento para el tratamiento de aguas residuales y residuos.
DE59007133D1 (de) Unterbrechungsfreie Stromversorgung.
IT8420584A1 (it) Processo elettrochimico per l'ossidazione di substrati organici con ossigeno molecolare
BR6602002U (pt) Estacao de tratamento de esgotos primario e secundario com aproveitamento de seus residuos finais
KR880007038U (ko) 정 부극성 절환용 스위치가 부착된 아답타
BR9805662A (pt) Sistema de convenrsão de instalações de tratamento de efluentes
IT1174794B (it) Membrana vaginale distrubutrice di spermicida
IT209556Z2 (it) Rubinetto di arresto con regolazione d'acqua e con filtro.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 599576

Country of ref document: ES